⌕
Rapport Therapeutics · RAPP · Nasdaq
Tenet 59 · Mixed
Compare
$24.82−5.09%At closeTenet 59 · Mixed
$24.82−1.33 (−5.09%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Rapport Therapeutics (RAPP) Stock

Rapport Therapeutics (RAPP) closed at $24.82 on Nov 16, 2026; its Tenet Score is 59 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

31 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$24.82
Nov 16, 2026
Market cap
$1.6B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
22.06 – 52.93
low → high · as of close, Nov 13, 2026
Tenet Score
59/100
Mixed · 313 Healthcare peers

Industry: Pharmaceutical Preparations

Rapport Therapeutics Inc. scores 59/100. Mixed. Strongest on financial health, quality is the soft spot versus 313 Healthcare peers. Insufficient inputs: Tenet 59 is built from 3 of 4 pillars, from 50% of its inputs. Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=313
59/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
55
Quality
30
Health
93
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueCQualityDHealthAGrowth—MomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
4.0×
price to book value
P/S
77.5×
price to fiscal 2025 sales
ROE
−33%
return on equity
Operating margin
—
no operating margin on file
Net margin
−752.4%
of revenue kept
Current ratio
20.07
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Rapport Therapeutics Inc.

We are a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (“CNS”) disorders. Neuronal receptors are complex assemblies of proteins,…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 65 US ETFs · top wrappers by weightSee all ETFs holding RAPP →

Similar-sized companies in Pharmaceutical Preparations

The 5 companies in this industry closest in market cap, as of Nov 13, 2026.

CompanyTenet ScoreMarket cap
MBX Biosciences Inc.MBX52$2.7B
Septerna Inc.SEPN54$2.0B
Zenas Biopharma Inc.ZBIO29$1.9B
Alto Neuroscience Inc.ANRO52$1.2B
Bicara Therapeutics Inc.BCAX61$685.1M

What sector and industry is Rapport Therapeutics in?

Rapport Therapeutics is in the Healthcare sector and the Pharmaceutical Preparations industry.

What is Rapport Therapeutics' Tenet Score?

Rapport Therapeutics' Tenet Score is 59 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.